Vorinostat's Effects on Endometrial Cancer Cells
Author Information
Author(s): Sarfstein Rive, Bruchim Ilan, Fishman Ami, Werner Haim
Primary Institution: Sackler School of Medicine, Tel Aviv University
Hypothesis
The study aims to establish whether vorinostat can modify the expression of specific genes related to the IGF-I receptor signaling pathway and revert the transformed phenotype.
Conclusion
Vorinostat exhibits a potent apoptotic and anti-proliferative effect in both Type I and II endometrial cancer cells.
Supporting Evidence
- Vorinostat increased IGF-IR phosphorylation and induced apoptosis in both cell lines.
- Vorinostat treatment led to a significant decrease in proliferation and colony forming capability in both cell lines.
- Vorinostat up-regulated p21 expression and reduced cyclin D1 levels.
Takeaway
Vorinostat is a drug that can help kill cancer cells in the uterus by changing how certain genes work.
Methodology
The study used human endometrial cancer cell lines treated with vorinostat to analyze gene expression and signaling pathways.
Limitations
The study primarily focuses on in vitro cell lines, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website